<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417767</url>
  </required_header>
  <id_info>
    <org_study_id>CHG－DAC 001</org_study_id>
    <secondary_id>SHDC12010202</secondary_id>
    <nct_id>NCT01417767</nct_id>
  </id_info>
  <brief_title>Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS</brief_title>
  <official_title>Phase 2/3 Study of Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiao Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 6th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of CHG regimen (low-dose cytarabine,
      homoharringtonine with G-CSF priming) to decitabine in the treatment of higher-risk
      myelodysplastic syndromes(MDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with higher-risk myelodysplastic syndrome (MDS) have a survival rate of 0.4 to 1.2
      years as well as a high risk of their disease progressing to acute myeloid leukemia (AML).
      The only treatment with a curative potential is allogeneic stem cell transplantation.
      However, in the majority of patients, this treatment is not applicable, mainly due to the age
      of the recipients and comorbid conditions. Low-dose chemotherapy CHG regimen (low-dose
      cytarabine, homoharringtonine with G-CSF priming)has been used to treat higher-risk MDS in
      China and achieve high response rate. Hypomethylating agents 5-aza-2'-deoxycytidine
      (decitabine) is nucleoside analogs that covalently bind to the DNA methyltransferases,
      irreversibly inhibiting their function, leading to the progressive loss of methylation and
      reversal of gene silencing. The purpose of this study is to compare the efficacy and safety
      of CHG regimen to Decitabine in higher-risk MDS.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>four weeks after one course of CHG or two courses of Decitabine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall remission rate</measure>
    <time_frame>four weeks after one course of CHG or two courses of Decitabine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematology toxicities</measure>
    <time_frame>within the first 4 weeks after CHG or Decitabine regimen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-hematologic toxicities</measure>
    <time_frame>within the first 4 weeks after CHG or Decitabine</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>CHG regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one course of CHG regimen (low-dose cytarabine, homoharringtonine and G-CSF priming)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one course of Decitabine (5-aza-deoxycytidine,Dacogen)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHG regimen</intervention_name>
    <description>cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.</description>
    <arm_group_label>CHG regimen</arm_group_label>
    <other_name>Low dose chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-aza-deoxycytidine</intervention_name>
    <description>Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.</description>
    <arm_group_label>Decitabine</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age rang from 16 to 80 years;

          -  diagnosis of higher-risk MDS (with≥ 5% blast in bone marrow);

          -  a performance status of 0-3 according to the Eastern Cooperative Oncology Group
             (ECOG);

          -  no evidence of severe concurrent cardiac, pulmonary, neurologic, or metabolic
             diseases;

          -  adequate hepatic (serum bilirubin level &lt;2×upper normal limit) and renal (serum
             creatinine &lt;2×upper normal limit) function tests.

        Exclusion Criteria:

          -  Female with pregnancy;

          -  a performance of 4-5 according to ECOG score;

          -  HIV positive;

          -  uncontrolled severe fungal infection or tuberculosis;

          -  with other progressive malignant diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao Li, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai 6th People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lingyun Wu, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai 6th People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chunkang Chang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 6th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao Li, Doctor</last_name>
    <phone>008621-64369181-58745</phone>
    <email>lixiao3326@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lingyun Wu, Doctor</last_name>
    <phone>008621-64369181-58336</phone>
    <email>wu_lingyun@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai 6th People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiao Li</last_name>
      <email>lixiao3326@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Xiao Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2011</study_first_submitted>
  <study_first_submitted_qc>August 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 6th People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiao Li</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>myelodysplastic syndromes</keyword>
  <keyword>Decitabine</keyword>
  <keyword>homoharringtonine</keyword>
  <keyword>cytarabine</keyword>
  <keyword>G-CSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Homoharringtonine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

